BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ShangPharma Accepts $9/ADS Go-Private Offer


12/27/2012 10:56:46 AM

by Richard Daverman, PhD

December 21, 2012 -- ShangPharma, a pre-clinical CRO headquartered in Shanghai’s Zhangjiang Hi-Tech Park, has agreed to a go-private offer of $9.00 per ADS. The offer was made by a group comprised of Michael Xin Hui, the company’s Chairman/CEO/Founder, and TPG, a US private equity group that has long been an investor in ShangPharma. Mr. Hui currently controls 54% of the company’s shares, while TPG still owns 11%. TPG will presumably fund at least some of the purchase of the remaining 35% of outstanding shares. The deal values ShangPharma at $173 million. More details....

Stock Symbol: (NYSE: SHP)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES